The European Commission has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide drug, Ozempic, as a treatment for adults with Type II diabetes. The GLP-1 analogue’s label in Europe recommends that the drug is given when metformin is contraindicated or not tolerated, Novo Nordisk reported today. Get the full story at our sister site, Drug Delivery Business News.
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
How the Apple Watch & other wearables could help highlight early signs of diabetes
Researchers have found that using Cardiogram‘s deep neural network technology, data collected from ordinary wearables could help flag early signs of diabetes. In one 14,000-person study, the company’s DeepHeart technology was able to distinguish between people with and without diabetes at 85% accuracy. Get the full story at our sister site, Drug Delivery Business News.
Abbott’s FreeStyle Libre glucose monitoring app launches in Europe
Abbott (NYSE:ABT) said today that it launched an app for its FreeStyle Libre glucose monitoring system in Europe that can be used with both iPhone and Android smartphones. The mobile app is designed to give people with diabetes direct access to their glucose data on their smartphones. Without the app, FreeStyle Libre users have to carry […]
Sales for Sanofi’s U.S. diabetes biz fall -30% in Q4
Shares in Sanofi (NYSE:SNY) fell today after the French pharmaceutical giant missed expectations on Wall Street with its 4th quarter and full-year financial results. The company faced particular challenges in its diabetes business, which saw its global sales plunge -14% in Q4. Revenues for Sanofi’s diabetes unit in the U.S. fell -29.5% compared to the same period […]
Machine-learning model helps detect diabetic patients at risk for kidney damage
Medial EarlySign touted data today from a study of its algorithm designed to identify diabetic patients who have the highest risk of developing renal dysfunction. The company’s machine-learning model looks at data from electronic health records to make predictions about patients’ health. In this study, the company reported that the algorithm identified 45% of patients who […]
Novo Nordisk launches two new diabetes drugs in U.S.
Novo Nordisk (NYSE:NVO) today launched two new diabetes medications in pharmacies across the U.S. The Danish company’s Ozempic product is a once-weekly GLP-1 receptor agonist designed to boost glycemic control in adults with Type II diabetes. The injection, administered in a pre-filled pen, won FDA approval in December. Get the full story at our sister site, Drug […]
Cam Med partners with JDRF to develop flexible, bandage-like insulin patch pump
Medical device startup Cam Med has partnered with JDRF to develop an ultra-thin, flexible insulin patch pump to be used with next-generation artificial pancreas systems. The goal of the partnership is to speed up the development of Cam Med’s Evopump – a conformable, disposable patch pump – so that the device can be integrated into closed-loop insulin delivery systems […]
Intarcia slashes headcount after FDA rejects diabetes drug-device combo
Four months after the FDA rejected its diabetes drug-eluting implant, privately-held Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports. The company’s device is designed for the continuous, subcutaneous delivery of exenatide in people with Type II diabetes. It was rejected by the U.S. regulatory agency in […]
Shares in Novo Nordisk sink after Q4 earnings, sales disappoint
Shares in Novo Nordisk (NYSE:NVO) fell today after the insulin-maker missed expectations on Wall Street with its fourth quarter and full-year financial results. The Denmark-based company posted profits of $1.38 billion on sales of $4.68 billion for the 3 months ended Dec. 31, for bottom-line loss of -5% on sales loss of -5% compared with the same […]
Nemaura Medical touts clinical trial data for non-invasive glucose monitor
Shares in Nemaura Medical (NSDQ:NMRD) jumped today after the company touted positive data from the European clinical trial program for its non-invasive sugarBeat glucose monitoring system. The summary results were taken from a 25-patient group in the three-stage trial, made up of 80% Type I diabetics and 20% Type II diabetics. Each patient continuously wore the sugarBeat […]
Arkray inks licensing deal with Mellitus Health for insulin titration software
Arkray‘s U.S. business has inked a licensing deal with Mellitus Healthfor its insulin titration software, Insulin Insights. Mellitus Health, formerly known as Insulin Algorithms, developed the clinical decision-support tool to help doctors keep their patients’ blood sugar levels in control with optimized insulin therapy. The software is compatible with any blood glucose monitoring system and with […]